Abstract Library

#4604 Germline predisposition to neuroendocrine tumours of the pancreas (pNEN) based on mutations in DNA repair genes – BRCA1, BRCA2, PALB2, CHEK2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MUTYH, STK11

Introduction: Neuroendocrine tumours of the pancreas (pNEN) rank as the second most common epithelial neoplasms after pancreatic adenocarcinoma, with increasing prevalence and a mortality rate of 60%. Identifying germline mutations in DNA repair genes such as CHEK2, BRCA1/2, and MUTYH within pNEN cases may pave the way for personalised diagnostics and therapies.

Conference:

Presenting Author:

Authors: Jurecka Lubieniecka B, Ros-Mazurczyuk M, Oczko-Wojciechowska M, Cortez A, Handkiewicz-Junak D,

Keywords: pNEN, DNA repair genes,

#4542 Results of active observation of pancreatic non-functioning neuroendocrine tumours – Medical registry data

Introduction: Algorithm for stage T1 pancreatic neuroendocrine tumours (PNETs) treatment requires clarification.

Conference:

Presenting Author:

Authors: Salimgereeva D, Feidorov I, Konyakhina A, Petrova A,

Keywords: Neuroendocrine tumour, PNET, pancreatic NET, management, active observation, follow-up, registry, CHEK2, oestrogen,

#4355 Emergence of DNA damage repair clonal haematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumours

Introduction: In neuroendocrine tumours (NETs), PRRT (Peptide Receptor Radionuclide Therapy), has shown efficacy but with significant hematologic toxicity. Clonal haematopoiesis (CHIP) is considered a risk factor for therapy-related myeloid neoplasms (t-MN).

Conference:

Presenting Author: Hadoux J

Authors: Loyaux R, Hadoux J, Oziel-Taieb S, Durand A, Bouhier Leporrier K,

Keywords: PRRT, clonal haematopoiesis, DNA Damage Repair, therapy-related myeloid neoplasm, Neuroendocrine tumour,

#4246 Prevalence of germline mutations in pancreatic neuroendocrine tumors

Introduction: Approximately 10% of pancreatic neuroendocrine tumors (PanNETs) develop due to inherited syndromes. However, generally genetic counseling and testing is not performed routinely and little accumulated on the prevalence of PanNETs associated with the presence of germline mutations.

Conference:

Presenting Author:

Authors: Salimgereeva D, Feidorov I, Konyakhina A,

Keywords: PanNET, GENOME, NGS, CHEK2, MEN1,

#3649 Influence of pathogenic somatic mutations on the survival rates of patients with neuroendocrine tumors of the gastrointestinal tract (NET GI)

Introduction: Genomic sequencing of 40 tumors samples from patients diagnosed with NET GI was performed. Further, according to the results obtained, the survival rates of patients were evaluated.

Conference:

Presenting Author: Androsova A

Authors: Androsova A, Orlova R, Gordiev M, Ivanova A, Belyak N,

Keywords: NET, mutations, BRCA, POLE, Genomic sequencing,